- Home
- CNEY vs VIVS Comparison
CNEY vs VIVS Comparison
Compare CNEY & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | VIVS |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | China | United States |
| Employees | N/A | 13 |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNEY | VIVS |
|---|---|---|
| Price | $0.82 | $1.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 136.1K | 108.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $1.42 |
| 52 Week High | $3.25 | $5.30 |
Technical Indicators
Market Signals| Indicator | CNEY | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 44.90 |
| Support Level | $0.54 | $1.75 |
| Resistance Level | $1.10 | $2.19 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 10.22 | 10.87 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.